Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.64 |
| ▸ | ERBB2 | P04626 | 9/20 | 0.63 |
| ▸ | ERBB4 | Q15303 | 3/20 | 0.63 |
| ▸ | GAK | O14976 | 2/20 | 0.63 |
| ▸ | ABL1 | P00519 | 2/20 | 0.63 |
| ▸ | LCK | P06239 | 2/20 | 0.63 |
| ▸ | MET | P08581 | 2/20 | 0.63 |
| ▸ | PHKG2 | P15735 | 2/20 | 0.63 |
| ▸ | BLK | P51451 | 2/20 | 0.63 |
| ▸ | IRAK1 | P51617 | 2/20 | 0.63 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.63 |
| ▸ | HIPK4 | Q8NE63 | 2/20 | 0.63 |
| ▸ | EPHA6 | Q9UF33 | 2/20 | 0.63 |
| ▸ | CIT | O14578 | 1/20 | 0.63 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.63 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.63 |
| ▸ | STK10 | O94804 | 1/20 | 0.63 |
| ▸ | LYN | P07948 | 1/20 | 0.63 |
| ▸ | RET | P07949 | 1/20 | 0.63 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15781156 | 0.95 | EGFR (0.64) | EGFRERBB2ERBB4GAKABL1 | |
| SCHEMBL15781150 | 0.90 | EGFR (0.65) | EGFRERBB2ERBB4GAKABL1 | |
| SCHEMBL15772999 | 0.83 | EGFR (0.80) | EGFRERBB2ERBB4GAKLCK | |
| SCHEMBL15773000 | 0.83 | EGFR (0.80) | EGFRERBB2ERBB4GAKLCK | |
| SCHEMBL15781161 | 0.82 | EGFR (0.74) | EGFRERBB2ERBB4GAKLCK | |
| SCHEMBL15781136 | 0.81 | EGFR (0.77) | EGFRERBB2ERBB4GAKLCK | |
| SCHEMBL15781133 | 0.81 | EGFR (0.80) | EGFRERBB2ERBB4GAKLCK | |
| SCHEMBL15090527 | 0.81 | EGFR (0.84) | EGFRERBB2ERBB4GAKLCK | |
| SCHEMBL15090569 | 0.81 | EGFR (0.84) | EGFRERBB2ERBB4GAKLCK | |
| Hydrochloric Acid SCHEMBL15104756 | 0.81 | EGFR (0.83) | EGFRERBB2ERBB4GAKLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9956222-B2 | Quinazoline derivative as tyrosine-kinase inhibitor, preparation method therefor and application thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2018-05-01 | — | — | US | disclosed |
| US-9956222-B2 | Quinazoline derivative as tyrosine-kinase inhibitor, preparation method therefor and application thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2018-05-01 | — | — | US | disclosed |
| US-20170136023-A1 | QUINAZOLINE DERIVATIVE AS TYROSINE-KINASE INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Xuanzhu Pharma Co., Ltd. (CN) | 2017-05-18 | — | — | US | disclosed |
| US-20170136023-A1 | QUINAZOLINE DERIVATIVE AS TYROSINE-KINASE INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Xuanzhu Pharma Co., Ltd. (CN) | 2017-05-18 | — | — | US | disclosed |
| EP-2716633-B1 | QUINAZOLINE DERIVATIVE AS TYROSINE-KINASE INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | XUANZHU PHARMA CO LTD (CN) | 2017-05-17 | — | — | EP | disclosed |
| US-9586939-B2 | Quinazoline derivative as tyrosine-kinase inhibitor, preparation method therefor and application thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2017-03-07 | — | — | US | disclosed |
| US-9586939-B2 | Quinazoline derivative as tyrosine-kinase inhibitor, preparation method therefor and application thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2017-03-07 | — | — | US | disclosed |
| US-20140161801-A1 | QUINAZOLINE DERIVATIVE AS TYROSINE-KINASE INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Xuanzhu Pharma Co., Ltd. (CN) | 2014-06-12 | — | — | US | disclosed |
| US-20140161801-A1 | QUINAZOLINE DERIVATIVE AS TYROSINE-KINASE INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Xuanzhu Pharma Co., Ltd. (CN) | 2014-06-12 | — | — | US | disclosed |
| WO-2012159457-A1 | QUINAZOLINE DERIVATIVE AS TYROSINE-KINASE INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 山东亨利医药科技有限责任公司 (CN) | 2012-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170136023-A1 | QUINAZOLINE DERIVATIVE AS TYROSINE-KINASE INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | JAK1, JAK2, YES1 | EGFR 194/4885ERBB2 53/4885ERBB4 109/4885 |
| US-20140161801-A1 | QUINAZOLINE DERIVATIVE AS TYROSINE-KINASE INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | JAK1, JAK2, YES1 | EGFR 194/4885ERBB2 53/4885ERBB4 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.